FrancophonIA/ELRC3.0 huggingface dataset:
English: Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), aplastic anaemia, pancytopenia, agranulocytosis, severe thrombocytopenia, granulocytopenia, anaemia
Maltese: Purpura tromboċitopenika trombotika (TTP) (ara sezzjoni 4.4), anemija aplastika, panċitopenja, agranuloċitosi, tromboċitopenja severa, granuloċitopenja, anemija Mard minn seru barrani, reazzjonijiet simili għal dawk anafilattiċi Alluċinazzjonijiet, konfużjoni
English: Pink, round, biconvex, engraved with «75» on one side and «1171» on the other side.
Maltese: Roża, tonda, konvessa miż-żewġ naħat, b' “75” imnaqqax fuq naħa waħda u “1171” imnaqqax fuq in
English: In a subgroup analysis by qualifying condition (myocardial infarction, ischaemic stroke, and PAD) the benefit appeared to be strongest (achieving statistical significance at p = 0.003) in patients enrolled due to PAD (especially those who also had a history of myocardial infarction) (RRR = 23.7%; CI: 8.9 to 36.2) and weaker (not significantly different from ASA) in stroke patients (RRR = 7.3%; CI: -5.7 to 18.7 [p=0.258]).
Maltese: F'analiżi tas-sottogrupp permezz ta' kundizzjoni qwalifikanti (infart mijokardijaku, puplesija iskemika, u PAD) il-benefiċċju jidher li kien l-ikbar (b'relevanza statistika ta' p = 0.003) f'pazjenti li ddaħħlu minħabba PAD (speċjalment dawk li kellhom ukoll storja medika ta' infart mijokardijaku) (RRR = 23.7%; CI: minn 8.9 sa 36.2) u inqas (mhux differenti b'mod sinifikanti minn ASA) f'pazjenti b'puplesija (RRR = 7.3%; CI: minn -5.7 sa 18.7 [p=0.258]).
English: In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both groups (0.6% versus 0.5% in the clopidogrel + ASA and the placebo + ASA groups,
Maltese: F'COMMIT, ir-rata totali ta' fsada maġġuri mhux ċerebrali jew ta' fsada ċerebrali kienet baxxa u simili fiż-zewġ gruppi (0.6% kontra 0.5% fil-gruppi clopidogrel + ASA u l-plaċebo + ASA, rispettivament).
English: Data from studies with human liver microsomes indicated that the carboxylic acid metabolite of clopidogrel could inhibit the activity of Cytochrome P450 2C9.
Maltese: Tagħrif minn studji b'mikrosomi tal-fwied uman indikaw li l-metabolit ta' carboxylic acid ta' clopidogrel jista jinibixxi l-attivita` ta' Cytochrome P450 2C9.
English: Patients were randomised to clopidogrel (300 mg loading dose followed by 75 mg/day, N=6,259) or placebo (N=6,303), both given in combination with ASA (75-325 mg once daily) and other standard therapies.
Maltese: Ilpazjenti kienu randomised għal clopidogrel (doża qawwija tal-bidu ta' 300 mg u wara 75 mg/jum, N = 6,259) jew il-plaċebo (N = 6,303), u t-tnejn ingħataw flimkien ma' ASA (75-325 mg darba kuljum) u terapiji oħra standard.
English: In patients suffering from acute coronary syndrome:
Maltese: • Pazjenti li għandhom is-sindromu koronarju akut:
English: EU/1/08/464/001 - Cartons of 14 film-coated tablets in PVC/PVDC/Alu blisters EU/1/08/464/002 - Cartons of 14 film-coated tablets in all aluminium blisters EU/1/08/464/003 - Cartons of 28 film-coated tablets in PVC/PVDC/Alu blisters EU/1/08/464/004 - Cartons of 28 film-coated tablets in all aluminium blisters EU/1/08/464/005 - Cartons of 30 film-coated tablets in PVC/PVDC/Alu blisters EU/1/08/464/006 - Cartons of 30 film-coated tablets in all aluminium blisters EU/1/08/464/007 - Cartons of 50x1 film-coated tablets in PVC/PVDC/Alu blisters EU/1/08/464/008 - Cartons of 50x1 film-coated tablets in all aluminium blisters EU/1/08/464/009 - Cartons of 84 film-coated tablets in PVC/PVDC/Alu blisters EU/1/08/464/010 - Cartons of 84 film-coated tablets in all aluminium blisters EU/1/08/464/011 - Cartons of 90 film-coated tablets in PVC/PVDC/Alu blisters EU/1/08/464/012 - Cartons of 90 film-coated tablets in all aluminium blisters EU/1/08/464/013 - Cartons of 100 film-coated tablets in PVC/PVDC/Alu blisters EU/1/08/464/014 - Cartons of 100 film-coated tablets in all aluminium blisters EU/1/08/464/018 - Cartons of 7 film-coated tablets in PVC/PVDC/Alu blisters EU/1/08/464/019 - Cartons of 7 film-coated tablets in all aluminium blisters
Maltese: EU/1/08/464/001 - Kaxex ta' 14-il pillola miksija b'rita fil-folji tal-PVC/PVDC/Alu EU/1/08/464/002 - Kaxex ta' 14-il pillola miksija b'rita fil-folji kollha kemm huma ta' l-aluminjum EU/1/08/464/003 - Kaxex ta' 28 pillola miksija b'rita fil-folji tal-PVC/PVDC/Alu EU/1/08/464/004 - Kaxex ta' 28 pillola miksija b'rita fil-folji kollha kemm huma ta' l-aluminjum EU/1/08/464/005 - Kaxex ta' 30 pillola miksija b'rita fil-folji tal-PVC/PVDC/Alu EU/1/08/464/006 - Kaxex ta' 30 pillola miksija b'rita fil-folji kollha kemm huma ta' l-aluminjum EU/1/08/464/007 - Kaxex ta' 50x1 pillola miksija b'rita fil-folji tal-PVC/PVDC/Alu EU/1/08/464/008 - Kaxex ta' 50x1 pillola miksija b'rita fil-folji kollha kemm huma ta' l-aluminjum EU/1/08/464/009 - Kaxex ta' 84 pillola miksija b'rita fil-folji tal-PVC/PVDC/Alu EU/1/08/464/010X/X/X/XXX - Kaxex ta' 84 pillola miksija b'rita fil-folji kollha kemm huma ta' l
English: Glycoprotein IIb/IIIa inhibitors: clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions that receive concomitant glycoprotein IIb/IIIa inhibitors (see section 4.4).
Maltese: Inibituri ta' Glycoprotein IIb/IIIa: clopidogrel għandu jintuża b'kawtela f'pazjenti li jista' jkollhom riskju ta' tkattir fid-dmija minħabba trawma, operazzjonijiet jew kundizzjonijiet patoloġiċi oħra li jirċievu l-inibituri ta' glycoprotein IIb/IIIa flimkien mal-prodott mediċinali (ara sezzjoni 4.4).
English: In CLARITY, there was an overall increase in bleeding in the clopidogrel + ASA group (17.4%) vs. the placebo + ASA group (12.9%).The incidence of major bleeding was similar between groups (1.3% versus 1.1% for the clopidogrel + ASA and the placebo + ASA groups, respectively).
Maltese: L-inċidenza ta' fsada maġġuri kienet simili bejn il-gruppi (1.3% kontra 1.1% għal gruppi clopidogrel + ASA u l-plaċebo + ASA, rispettivament).
English: In patients who remained on therapy within five days of bypass graft surgery, the event rate was 9.6% for clopidogrel+ASA, and 6.3% for placebo+ASA.
Maltese: F'pazjenti li baqgħu jieħdu l-kura fil-ħamest ijiem ta' qabel l-operazzjoni ta' trapjant ta' bajpass, ir-rata ta' avvenimenti kienet ta' 9.6% għal clopidogrel+ASA, u 6.3% għal placebo+ASA.
English: The benefits observed with clopidogrel were independent of other acute and long-term cardiovascular therapies (such as heparin/LMWH, GPIIb/IIIa antagonists, lipid lowering medicinal products, beta blockers, and ACE-inhibitors).
Maltese: Il-benefiċċji osservati bi clopidogrel kienu indipendenti minn terapiji kardjovaskulari oħra akuti u fittul (bħall- heparin/LMWH, antagonisti ta' GPIIb/IIIa, prodotti mediċinali li jbaxxu l-lipidi, imblokkaturi tar-riċetturi beta, u inibituri ta' ACE).
English: Clopidogrel BMS is supplied in cardboard cartons containing 7, 14, 28, 30, 84, 90 and 100 tablets in PVC/PVDC/Aluminium blisters or in all aluminium blisters, or 50x1 tablets in PVC/PVDC/Aluminium blisters or in all aluminium perforated unit-dose blisters.
Maltese: Il-pilloli miksija b'rita ta' Clopidogrel BMS 75-mg huma tondi, konvessi miż-żewġ naħat, ta' kulur roża, pilloli miksija b'rita bin-numru ‘75' imnaqqax fuq naħa waħda u n-numru ‘1171' imnaqqax fuq in-naħa l-oħra. Clopidogrel BMS huwa fornut f'kaxex tal-kartun li fihom 7, 14, 28, 30, 84, 90 u 100 pilloli ġo folji tal-PVC/PVDC/Aluminju jew ġo folji magħmulin kollha mill-aluminju, jew 50x1 pilloli f'folji tal-PVC/PVDC/Aluminju jew f'folji mtaqqbin b'doża waħda kollha kemm huma ta' l-aluminju.
English: For the 7, 14, 28 and 84 tablets pack sizes, you can check the day on which you last took a tablet of Clopidogrel BMS by referring to the calendar printed on the blister.
Maltese: Għall-pakketti ta' 7, 14, 28 u 84 pilloli, tista' tiċċekkja l-ġurnata li fiha ħadt l-aħħar il-pillola ta' clopidogrel billi tirreferi għall-kalendarju stampat fuq il-folja.
English: The number of patients experiencing the co-primary endpoint (CV death, MI, stroke or refractory ischaemia) was 1,035 (16.5%) in the clopidogrel-treated group and 1,187 (18.8%) in the placebotreated group, a 14% relative risk reduction (95% CI of 6%-21%, p=0.0005) for the clopidogrel-treated group.
Maltese: In-numri ta' pazjenti li kellhom punt ko-primarju ta' tmiem (mewt b'CV, MI, puplesija jew iskemija li mhux qed tirrisondi għall-kura) kien 1 035 (16.5%) fil-grupp ikkurat bi clopidogrel u 1 187 (18.8%) fil-grupp ikkurat bil-plaċebo, tnaqqis ta' 14% fir-riskju relattiv) (95% CI ta' 6%-21%, p= 0.0005) għall-grupp ikkurat bi clopidogrel.
English: MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER / Box of 4x1, 30x1 or 100x1 tablets
Maltese: FOLJA/kaxxa ta' 4x1, 30x1 jew 100x1 pilloli
English: Other alleles associated with reduced metabolism include CYP2C19*4, *5, *6, *7, and *8, but these are less frequent in the general population.
Maltese: Alleli oħra assoċjati ma' tnaqqis fil metaboliżmu jinkludu CYP2C19*4, *5, *6, *7, u *8, iżda dawn huma anqas frekwenti fil-popolazzjoni ġenerali. Frekwenzi ppubblikati għall-fenotipi u l-ġenotipi CYP2C19 komuni huma elenkati fit-tabella ta' hawn taħt.
English: If you have experienced severe chest pain (unstable angina or heart attack), your doctor may give you 300 mg of Clopidogrel BMS (1 tablet of 300 mg or 4 tablets of 75 mg) once at the start of treatment.
Maltese: Jekk kellek uġigħ sever f'sidrek (anġina instabbli jew attakk tal-qalb), it-tabib jista' jagħtik 300 mg ta' Clopidogrel BMS (pillola 1 ta' 300 mg jew 4 pilloli ta' 75 mg) darba fil-bidu tal-kura.
English: Not applicable
Maltese: .2 Inkompatibilitajiet
English: However, patients entered into clinical trials with clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers, ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents and GPIIb/IIIa antagonists without evidence of clinically
Maltese: Madankollu, pazjenti li daħlu fi studji kliniċi bi clopidogrel ngħataw varjeta` ta' prodotti mediċinali fl-istess ħin u dawn kienu jinkludu dijuretiċi, beta blockers, ACEI, antagonisti tal-kalċju, sustanzi li jbaxxu l-kolesterol, vasodilataturi koronarji, sustanzi kontra d-dijabete (inkluża l-insulina), sustanzi antiepilettiċi, u antagonisti GPIIb/IIIa mingħajr ma kien hemm evidenza ta' interazzjonijiet avversi klinikament sinifikanti.
English: Clopidogrel BMS 300-mg film-coated tablets are oblong, pink, engraved on one side with the number ‘300' and on the other side with the number ‘1332'.
Maltese: Id-dehra ta' Clopidogrel BMS u l-kontenuti tal-pakkett Il-pilloli miksija b'rita ta' Clopidogrel BMS 300 mg huma oblungi, ta' kulur roża, pilloli miksija b'rita bin-numru ‘300' imnaqqax fuq naħa waħda u n-numru ‘1332' imnaqqax fuq in-naħa l-oħra.
English: Thrombolytics: the safety of the concomitant administration of clopidogrel, fibrin or non-fibrin specific thrombolytic agents and heparins was assessed in patients with acute myocardial infarction.
Maltese: Trombolitiċi: is-sigurta` tat-teħid flimkien ta' clopidogrel, sustanzi trombolitiċi speċifiċi għall-fibrina jew li m'humiex u heparin ġiet eżaminata f'pazjenti li kellhom infart mijokardijaku akut.
English: Following an oral dose of 14C-labelled clopidogrel in man, approximately 50% was excreted in the urine and approximately 46% in the faeces in the 120-hour interval after dosing.
Maltese: Wara doża orali ta' clopidogrel 14C-tikkettatfil-bniedem, bejn wieħed u ieħor 50% kien mneħħi fl urina u bejn wieħed u ieħor 46% ħareġ fl-ippurgar fl-intervall ta' 120 siegħa wara d-dożaġġ.
English: Ísland
Maltese: Norge
English: It also contains: hydrogenated castor oil and lactose.
Maltese: Fiha wkoll: lactose u castor oil idroġenat.
English: Absorption is at least 50%, based on urinary excretion
Maltese: L-assorbiment huwa millinqas ta' 50%, skond l-eskrezzjoni fl-urina ta' metaboliti ta' clopidogrel.
English: If you forget to take Clopidogrel BMS:
Maltese: Oqgħod attent ħafna b' Clopidogrel BMS :
English: − Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): clopidogrel treatment should be initiated with a single 300 mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily).
Maltese: - Bis-segment mhux ST elevat (anġina instabbli jew infart mijokardijaku mhux-mewġa-Q): il-kura bi clopidogrel għandha tinbeda b'doża waħda qawwija tal-bidu ta' 300 mg u titkompla b'75 mg darba kuljum (b'acetylsalicylic acid (ASA) 75 mg-325 mg kuljum).
English: - Clopidogrel BMS 300 mg film-coated tablets
Maltese: - Clopidogrel BMS 300 mg pilloli miksija b'rita
English: In particular, in a post-hoc analysis in 2,172 patients (17% of the total CURE population) who underwent stent placement (Stent-CURE), the data showed that clopidogrel compared to placebo, demonstrated a significant RRR of 26.2% favouring clopidogrel for the co-primary endpoint (CV death, MI, stroke) and also a significant RRR of 23.9% for the second coprimary endpoint (CV death, MI, stroke or refractory ischaemia).
Maltese: Partikularment, f'analiżi post-hoc f' 2172 pazjent (17% tal-popolazzjoni kollha CURE) li kellhom stent impoġġija (Stent-CURE), id-data wriet li clopidogrel, imqabbel ma plaċebo, wera RRR sinifikanti ta' 26.
English: CYP2C19 Phenotype and Genotype Frequency Frequency (%)
Maltese: Il-frekwenza tal-ġenotip u fenotip CYP2C19
English: Sanofi Winthrop Industrie
Maltese: Sanderson Road
English: PVC/PVDC/Aluminium or all aluminium perforated unit-dose blister packs in cardboard cartons containing 50x1 film-coated tablets.
Maltese: Pakketti ta' folji mtaqqbin ta' doża waħda tal-PVC/PVDC/Aluminju jew kollha kemm huma ta' laluminju f'kaxxi tal-kartun li fihom 50x1 pilloli miksijin b'rita.
English: 6, boulevard de l'Europe, F-21800 Quétigny, France
Maltese: 6, boulevard de l'Europe, F-21800 Quétigny, Franza Għal kull tagħrif dwar din il-mediċina, jekk jogħġbok, ikkuntattja lir-rappreżentant lokali tad-detentur ta' l-awtorizzazzjoni għat-tqegħid fis-suq.
English: Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Maltese: Pazjenti li għandhom problemi ereditarji rari ta' intolleranza għallgalactose, nuqqas ta' Lapp lactase jew malassorbiment ta' glucose-galactose m'għandhomx jieħdu dan
English: After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min), inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects, however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day.
Maltese: Wara dożi ripetuti ta' 75 mg ta' clopidogrel kuljum, f'persuni b'mard sever tal-kliewi (tneħħija talkreatinina minn 5 sa 15 ml/min), l-inibizzjoni ta' l-agreggrazzjoni tal-plejtlets indotti minn ADP kien iktar baxx (25%) minn dak osservat f'persuni f'saħħithom, madankollu it-titwil fil-ħin tad-dmija kien simili għal dak osservat f'persuni f'saħħithom li kienu qed jingħataw 75 mg ta' clopidogrel kuljum.
English: VISTOR HF
Maltese: STRUZZJONIJIET DWAR L-UŻU
English: Since clopidogrel is metabolised to its active metabolite partly by CYP2C19, use of drugs that inhibit the activity of this enzyme would be expected to result in reduced drug levels of the active metabolite of clopidogrel and a reduction in clinical efficacy.
Maltese: Peress li parti mill-metaboliżmu ta' clopidogrel għall-metabolit attiv tiegħu jsir minn CYP2C19, huwa mistenni li l-użu ta' mediċini li jinibixxu l-attività ta' din l-enzima jwasslu għal tnaqqis fil-livell talmetabolit attiv ta' clopidogrel u għal tnaqqis fl-effikaċja klinika.
English: INFORMATION IN BRAILLE
Maltese: Carnauba wax
English: BMS;
Maltese: Kft.
English: Marketing Authorisation Holder and Manufacturer:
Maltese: Id-Detentur ta' l-Awtorizzazzjoni għat-Tqegħid fis-Suq u l-Manifattur:
English: Concomitant use of drugs that inhibit CYP2C19 should be discouraged (see sections 4.4 and 5.2).
Maltese: L-użu fl-istess waqt ta' mediċini li jimpedixxu CYP2C19 għandu jiġi skoraġġut (ara sezzjonijiet 4.4 u 5.2).
English: Hepato-biliary disorders
Maltese: Indeboliment epatiku
English: Clopidogrel BMS 75 mg film-coated tablets clopidogrel
Maltese: Clopidogrel BMS 75 mg pilloli miksija b'rita clopidogrel
English: - Clopidogrel BMS 75 mg film-coated tablets
Maltese: TAL-PRODOTT MEDIĊINALI Clopidogrel BMS 75 mg pilloli miksija b'rita
English: Data from the CAPRIE study indicate that phenytoin and tolbutamide can be safely co-administered with clopidogrel.
Maltese: Tagħrif mill-istudju CAPRIE jindika li phenytoin u tolbutamide jistgħu jiġu amministrat b'sigurta` flimkien ma' clopidogrel.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 300 mg of clopidogrel (as hydrogen sulphate).
Maltese: Kull pillola miksija b'rita fiha 300 mg ta' clopidogrel (bħala hydrogen sulphate ).
English: Very rare side effects (affects less than 1 patient in 10,000): Jaundice; severe abdominal pain with or without back pain; fever, breathing difficulties sometimes associated with cough; generalised allergic reactions; swelling in the mouth; blisters of the skin; skin allergy; inflammation of the mouth
Maltese: Effetti sekondarji rari ħafna (jaffettwaw anqas minn pazjent 1 minn kull 10,000): Suffejra; uġigħ addominali qawwi flimkien ma' jew mingħajr uġigħ fid-dahar; deni, diffikultajiet fin-nifs kultant assoċjati mas-sogħla; reazzjonijiet allerġiċi ġeneralizzati; nefħa fil-ħalq; infafet fil-ġilda; reazzjoni allerġika fil-ġilda; infjammazzjoni tal-ħalq (stomatite); tnaqqis fil-pressjoni tad-demm; konfużjoni; alluċinazzjonijiet; uġigħ fil-ġogi; uġigħ muskolari; tibdiliet fil-mod ta' kif jintegħmu l-affarijiet.
English: • You should also tell your doctor immediately if you develop a medical condition that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice) (see section 4
Maltese: • Għandek ukoll tgħid lit-tabib tiegħek minnufih jekk tiżviluppa kundizzjoni medika li tinkludi deni u tbenġil taħt il-ġilda li jidher bħal tikek ħomor irqaq, flimkien ma' jew mingħajr għeja kbira mhux spjegata, konfużjoni, sfurija tal-ġilda jew ta' l-għajnejn (suffejra) (ara sezzjoni 4
English: - ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.
Maltese: Infart mijokardijaku akut b'segment ST elevat, flimkien ma' ASA f'pazjenti ittrattati bilmediċini u eliġibbli għat-terapija trombolitika
English: Although the evidence of CYP2C19 inhibition varies within the class of Proton Pump Inhibitors, clinical studies suggest an interaction between clopidogrel and possibly all members of this class.
Maltese: Għalkemm l-evidenza ta' inibizzjoni ta' CYP2C19 tvarja fil-klassi ta' Inibituri tal-Pompa Protonika, studji kliniċi jissuġġerixxu xi interazzjoni bejn clopidogrel u wisq probabbli l-membri kollha ta' dan il-grupp.
English: Clopidogrel BMS 300-mg film-coated tablets clopidogrel
Maltese: Clopidogrel BMS 300 mg pilloli miksija b'rita clopidogrel
English: If you have experienced severe chest pain (unstable angina or heart attack), you may be prescribed Clopidogrel BMS in combination with acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever.
Maltese: Jekk ħassejt uġigħ qawwi f'sidrek (anġina mhux stabbli jew attakk tal-qalb), jista' jingħatalek Clopidogrel BMS flimkien ma' acetylsalicylic acid, sustanza inkorporata f'ħafna mediċini użati biex itaffu l-uġigħ u jnaqqsu d-deni.
English: España
Maltese: Österreich
English: - signs of liver problems such as yellowing of the skin and/or the eyes (jaundice), whether or not associated with bleeding which appears under the skin as red pinpoint dots and/or confusion (see section 2 ‘Take special care with Clopidogrel BMS').
Maltese: Madanakollu, jekk id-demm li ħiereġ jinkwetak, għandek tkellem lit-tabib tiegħek minnufih (ara sezzjoni 2 'Oqgħod attent ħafna b' Clopidogrel BMS ').
English: NAME OF THE MEDICINAL PRODUCT Clopidogrel BMS 75 mg film-coated tablets clopidogrel
Maltese: TAL-PRODOTT MEDIĊINALI Clopidogrel BMS 75 mg pilloli miksija b'rita clopidogrel
English: Tel.: + 48 22 5796666 Portugal
Maltese: Bristol-Myers Squibb Polska Sp. z o.o. Tel.: + 48 22 5796666
English: As with other antiplatelet agents, clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with ASA, heparin, glycoprotein IIb/IIIa inhibitors, or non-steroidal anti-inflammatory drugs (NSAIDs) including Cox-2 inhibitors.
Maltese: Bħal fil-każ ta' sustanzi oħra kontra l-plejtlets, clopidogrel għandu jintuża b'kawtela ma' pazjenti li jista' jkollhom riskju ta' iktar dmija minn trawma, operazzjoni jew kundizzjonijiet patoloġiċi oħra u pazjenti li jkunu qed jirċievu l-kura b'ASA, heparin, inibituri ta' glycoprotein IIb/IIIa, jew mediċini kontra l-infjammazzjoni li m'humiex sterojdi (NSAIDs) li jinkludu l-inibituri ta' Cox-2.
English: New cardiovascular events
Maltese: KLASSIFIKAZZJONI ĠENERALI
English: NAME OF THE MEDICINAL PRODUCT Clopidogrel BMS 300 mg film-coated tablets clopidogrel
Maltese: TAL-PRODOTT MEDIĊINALI Clopidogrel BMS 300 mg pilloli miksija b'rita clopidogrel
English: No effect on hepatic metabolising enzymes was observed in humans receiving clopidogrel at the therapeutic dose.
Maltese: Ma ġiex osservat effett fuq l-enzimi metabolizzanti tal-fwied fi bnedmin li kienu qed jingħataw clopidogrel b'doża terapewtika.
English: Tel: + 421 2 59298411 Suomi/Finland
Maltese: Slovenská republika Bristol-Myers Squibb spol. s r.o. Tel: + 421 2 59298411
English: Clopidogrel has been evaluated for safety in more than 42,000 patients who have participated in clinical studies, including over 9,000 patients treated for 1 year or more.
Maltese: Clopidogrel ġie evalwat għas-sigurta` f'iktar minn 42,000 pazjent li pparteċipaw fi studji kliniċi, inklużi iktar minn 9,000 pazjent li kienu kkurati bih għal sena jew iktar.
English: • if you have a risk of bleeding such as - a medical condition that puts you at risk of internal bleeding (such as a stomach ulcer) - a blood disorder that makes you prone to internal bleeding (bleeding inside any tissues, organs or joints of your body).
Maltese: • jekk tinsab f'riskju ta' fsada bħal: kundizzjoni medika li tpoġġik f'riskju ta' fsada interna (bħal ulċera fl-istonku) mard fid-demm li jwassal għal fsada interna (dmija f'xi tessuti, organi jew ġogi ta' ġismek); ferita serja riċenti; operazzjoni riċenti (anki tas-snien); operazzjoni li ser issirlek (anki tas-snien) fis-sebat ijiem li ġejjin.
English: NAME OF THE MEDICINAL PRODUCT Clopidogrel BMS 300 mg film-coated tablets
Maltese: TAL-PRODOTT MEDIĊINALI Clopidogrel BMS 300 mg pilloli miksija b'rita
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen sulphate).
Maltese: Kull pillola miksija b'rita fiha 75 mg clopidogrel (bħala hydrogen sulphate).
English: While you are taking Clopidogrel BMS:
Maltese: Jekk tieħu Clopidogrel BMS aktar milli suppost:
English: Clopidogrel BMS is taken to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as
Maltese: Clopidogrel BMS jittieħed biex inaqqas ir-riskju li ċapep tad-demm (trombi) jifformaw fl-arterji mwebbsin (arterji), proċess imsejjaħ aterotrombożi, li jista' jwassal għal konsegwenzi aterotrombotiċi (bħal puplesija, attakk tal-qalb, jew mewt).